If you suffered substantial losses and wish to serve as lead plaintiff of the Marqeta class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-marqeta-inc-class-action-lawsuit-mq.html

You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com.

CASE ALLEGATIONS: Marqeta operates a cloud-based open application programming interface platform that delivers card issuing and transaction processing services.

The Marqeta class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Marqeta understated the regulatory challenges affecting its business outlook; and (ii) as a result, Marqeta would have to cut its guidance for the fourth quarter of 2024.

The Marqeta class action lawsuit further alleges that on November 4, 2024, Marqeta revealed fourth quarter 2024 guidance of 10-12% net revenue growth and 13-15% gross profit growth, as opposed to the previously projected 16-18% net revenue growth and 22-24% gross profit growth figures, which “reflects several changes that became apparent over the last few months with regards to the heightened scrutiny of the banking environment and specific customer program changes.” On this news, the price of Marqeta stock fell more than 42%, according to the complaint.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Marqeta securities during the Class Period to seek appointment as lead plaintiff in the Marqeta class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Marqeta class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Marqeta class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Marqeta class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud cases. Our Firm has been #1 in the ISS Securities Class Action Services rankings for six out of the last ten years for securing the most monetary relief for investors. We recovered $6.6 billion for investors in securities-related class action cases – over $2.2 billion more than any other law firm in the last four years. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 
Services may be performed by attorneys in any of our offices. 

Contact:
        Robbins Geller Rudman & Dowd LLP
        J.C. Sanchez, Jennifer N. Caringal
        655 W. Broadway, Suite 1900, San Diego, CA 92101
        800-449-4900
        info@rgrdlaw.com

Click here to participate in the action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Joint Stock Company Kaspi.kz continued doing business with Russian entities, and also providing services to Russian citizens, after Russia’s 2022 invasion of Ukraine, thereby exposing the Company to the undisclosed risk of sanctions; (2) the Company engaged in undisclosed related party transactions; (3) certain of the Company’s executives have links to reputed criminals; and (4) as a result, defendants’ statements about Joint Stock Company Kaspi.kz’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you purchased or otherwise acquired Kaspi shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com

Fredericton, New Brunswick, Dec. 20, 2024 (GLOBE NEWSWIRE) — NextGen Digital Platforms Inc. (CSE:NXT) (“NextGen” or the “Company”) is pleased to provide corporate updates on its existing business platforms, and to announce its new strategic expansion to acquire and hold positions in certain cryptocurrencies, including Solana (“SOL”), XRP (“Ripple”), and Dogecoin (“DOGE”).

Business Progress Updates

The AI-powering workstation purchases previously announced by the Company on November 28, 2024, are now in delivery, following logistical challenges by the Company’s initial supplier and the Company’s ensuing engagement of a new supplier to ensure timely procurement. These workstations will expand the Company’s hardware-as-a-service business known as its “Cloud AI Hosting” fleet, which represents a revenue-generating business that the Company continues to grow. Cloud AI Hosting was developed in-house by NextGen.

Additionally, the Company is pleased to report the successful completion of a social media marketing campaign for its e-commerce platform, PCSections.com (“PCS”). PCS has generated increased revenue relative to the prior fiscal quarter. PCS was developed in-house by NextGen and has been in operation for approximately two years.

Strategic Expansion

Consistent with NextGen’s longstanding mission to develop and acquire revenue-generating micro-technology digital platforms, the Company is excited to announce the launch of its third business line, which is intended to provide NextGen and its investors with exposure to the rapidly expanding cryptocurrency sector. This also helps diversify the Company’s technology holdings across e-commerce, artificial intelligence, and now Web3.

The Company’s strategic expansion to acquire and hold SOL, Ripple and DOGE is expected to establish NextGen as a publicly traded proxy for this curated basket of cryptocurrencies, enabling investors to access the growing digital asset market through traditional equity markets.

This expansion also leverages NextGen’s past exposure to the cryptocurrency sector through its inaugural platform, CryptoASICMining.com (“CAM”), the predecessor to PCS, as described in the Company’s press release dated November 29, 2024. While CAM ultimately evolved into PCS, which remains the Company’s first digital platform, it provided the Company’s leadership and operational personnel with valuable experience in digital asset infrastructure, and a better understanding of the potential opportunities within the sector.

As the digital asset market continues to rapidly evolve and mature, so must the Company. This strategic expansion reflects another step in the Company’s evolution and broadens NextGen’s mission to include democratizing access to cryptocurrencies by providing investors with exposure to digital assets, without some of the complexities associated with direct cryptocurrency ownership. With this third business, NextGen adds a corporate objective of becoming a public entity providing exposure to a diversified cryptocurrency basket.

About Solana, XRP, and Dogecoin

1. Solana (SOL)

Solana is a high-speed, low-cost, large-scale blockchain platform launched in 2020. Having the capabilities to support up to 65,000 transactions per second at significantly low speeds, Solana is a leading platform for a large variety of decentralized finance (“DeFi”), non-fungible tokens (“NFTs”), and Web3 applications⁽¹⁾⁽²⁾. Solana’s growing developer ecosystem and widespread adoption make it a cornerstone of the cryptocurrency market.

NextGen’s Perspective:

By acquiring and holding Solana, NextGen intends to capitalize on the demand for marquee DeFi and blockchain-based applications and solutions, offering investors exposure to – in the opinion of management – one of the most promising and advanced ecosystems in the digital asset space.

2. XRP (Ripple)

XRP, developed by Ripple Labs, is a high-speed, scalable, and decentralized public blockchain aiming to improve global payments by enabling faster, cheaper, and more reliable cross-border transactions. Unlike traditional payment systems, which in some case may take days to settle, XRP proposes to facilitate near-instantaneous transactions at a fraction of the cost⁽³⁾.

NextGen’s Perspective:

NextGen views XRP as an important asset in the future of global institutional finance, offering investors exposure to a cryptocurrency that aims to bridge the gap between blockchain and traditional banking systems.

3. Dogecoin (DOGE)

Initially launched as a meme-based open-source, peer-to-peer cryptocurrency, Dogecoin has evolved into an accepted digital asset real-world transactional utility. Supported by a passionate community and high-profile endorsements, Dogecoin is increasingly used for micropayments, tipping, and e-commerce⁽⁴⁾. Its cultural relevance and simplicity make it an accessible entry point for new cryptocurrency users.

NextGen’s Perspective:

By acquiring and holding Dogecoin, NextGen hopes to opportunistically access mainstream adoption, providing investors with the opportunity to be a part of the expected growth and popularity of a community-driven cryptocurrency.

Interim Chief Executive Officer’s Statement:

“Our strategic expansion aligns with NextGen’s long-time mission, through which we give our investors exposure to exciting emerging micro-technology digital platforms that we have incubated or acquired. Through this expansion, we at NextGen hope to democratize cryptocurrency investing. By becoming a public proxy for a curated basket of these selected cryptocurrencies, we intend to offer investors a gateway into the digital asset economy. This strategy reflects our confidence in the long-term potential of blockchain technology and its impact on finance, commerce, and society,” said Alexander Tjiang, Interim CEO of NextGen.

Additional Corporate Developments

Further to the Company’s news release of December 20, 2024, in which the Company announced its three-month marketing engagement with Machai Capital Inc. (“Machai”), the Company has entered into an amending agreement with Machai dated December 20, 2024 (the “Machai Amending Agreement”) to amend the marketing services agreement with Machai (the “Original Machai Agreement”). Pursuant to the Machai Amending Agreement, the Company and Machai have agreed to decrease Machai’s marketing budget from C$155,000 (plus GST) to C$75,000 (plus GST) (the “Machai Budget”). All other terms of the Original Machai Agreement remain unamended. For more information regarding the Company’s engagement of Machai, please refer to its news release dated December 20, 2024. Machai and its principles’ directly own 954,042 common shares of the company.

Market Opportunity

As global cryptocurrency adoption continues to accelerate, the market for publicly traded proxies that enable investors access into the digital asset space has become increasingly more important. Crypto activity and usage have reached all-time highs, with ~220 million active addresses as of September 30, 2024⁽⁵⁾. However, barriers such as regulatory uncertainty, custodial complexities, and technical knowledge gaps limit direct access for many investors.

NextGen hopes to bridge this gap by offering an accessible alternative to direct cryptocurrency investments.

About NextGen Digital Platforms Inc.

NextGen Digital Platforms Inc. (CSE: NXT) is listed on the Canadian Securities Exchange. The Company currently operates e-commerce platform PCSections.com (“PCS”) and a hardware-as-a-service business supporting the artificial intelligence sector, called cloud AI hosting (“Cloud AI Hosting”). Both PCS and Cloud AI Hosting were developed in-house by NextGen. The Company also intends to democratize access to cryptocurrencies by providing investors with exposure to a diversified basket of digital assets through a regulated public vehicle. From time to time, the Company also intends to evaluate and acquire or develop other micro-technology platforms.

For More Information:

Alexander Tjiang, Interim Chief Executive Officer
(416) 300-7398
https://nextgendigital.ca/
‎info@nextgendigital.ca

Caution Regarding Forward-Looking Information

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release includes certain “forward-looking information” within the meaning of applicable Canadian securities legislation. All statements herein, other than statements of historical fact, constitute forward-looking information. Forward-looking information is frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “estimates”, “potential”, “possible”, and similar expressions, or statements that events, conditions, or results “will”, “may”, “could”, or “should” occur or be achieved.

Forward-looking information in this press release includes, but is not limited to, statements regarding the delivery and operation of workstations for Cloud AI Hosting, the Company’s future cryptocurrency investing plans and strategies, the Company’s proposed strategic expansion and growth strategies, the Company’s ability to provide investors with exposure to digital assets, the potential success of its investments and its brand, the growth of Solana, XRP, DOGE and other digital assets and the mainstream adoption of various cryptocurrencies. Forward-looking information reflects the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, including those pertaining to timely workstation delivery, cryptocurrency adoption, and the Company’s ability to execute its cryptocurrency business strategy, that, while considered reasonable by the Company, are inherently subject to significant business, technical, economic, and competitive uncertainties and contingencies, including the speculative nature of cryptocurrencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking information. Such risks, uncertainties and other factors include, without limitation, the Company’s ability to execute on its business and investment plans; operational and technological risks relating to Cloud AI Hosting; the Company’s ability to raise debt or equity through future financing activities; the Company’s ability to increase its investments in cryptocurrency-based technologies; any adverse changes and developments regarding Solana, XRP, DOGE or the cryptocurrency ecosystem; the growth and development of decentralized finance and the digital asset sector; any new rules and regulations with respect to decentralized finance and digital assets; the inherent volatility in the prices of certain cryptocurrencies including Solana, XRP and DOGE; increasing competition in the crypto and blockchain industries; general economic, political and social uncertainties in Canada and the United States; currency exchange rates and interest rates; the limited financial and personnel resources of the Company; the Company’s reliance on the expertise and judgment of senior management and the Company’s ability to attract and retain key personnel; the speculative nature of cryptocurrencies in general; and the Company’s ability to continue as a going concern.

There can be no assurance that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. The Company undertakes no obligation to update forward-looking statements herein except as required by applicable securities laws. Investors are cautioned against attributing undue certainty to forward-looking statements herein.

____________________

1. https://solana.com

2. https://ecos.am/en/blog/what-is-cryptocurrency-solana-sol-and-how-does-it-work/?srsltid=AfmBOoppeVpSvQe6PMDOa2kYI1ZYWMo2PgIpSsa5jMBf6Av4eMh4BU4a

3. https://xrpl.org

4. https://dogecoin.com

5. a16z, State of Crypto Report (2024), Sensor Tower

The post Inauguration of 17 Bus Routes Connecting Ben Thanh – Suoi Tien Metro appeared first on Vietnam Insider.

The post Thua Thien Hue to Have a Nearly 450-Hectare Golf Resort appeared first on Vietnam Insider.

By CNBC

By CNBC

Diamond Certified Guide to Winter-Related Services

Petaluma, CA, Dec. 19, 2024 (GLOBE NEWSWIRE) — American Ratings Corporation (ARC) has launched an expansive online guide to winter-related services on its highly trafficked Diamond Certified Resource website, diamondcertified.org. This guide offers 16 researched articles, tips, and resources that are designed to help Bay Area residents stay prepared for all of their winter projects and needs.

“Your Seasonal Guide to Winter-Related Services” is divided into four sections: Before, During, After and Essentials. From preparing your car for winter road safety to choosing the right furnace filter, there’s something for nearly every aspect of the season. Consumers can also get access to exclusive tips from Diamond Certified Expert Contributors and a helpful maintenance calendar, all designed to enhance the winter experience.

“People want to know which companies are high-quality and how to best work with the company they ultimately choose,” says ARC CEO Greg Louie. “That’s why we’ve created this deep category resource guide to help them this winter. When they read the 16 key articles and see links to pages where Diamond Certified companies are presented, they’ll feel more confident that they’re ready to take on the season.”

The Unique Diamond Certified Rating Process
The Diamond Certified 12-step rating process is highly accurate and based on real data. Only companies that score Highest in Quality and Helpful Expertise earn Diamond Certified. What really separates Diamond Certified ratings from the star score averages at review sites is that a large, random sample of each company’s customers are surveyed by phone to get the most accurate ratings and verify only real customers are responding. By surveying from a company’s entire customer base, each company’s research results truly represent its customer satisfaction level. Most companies can’t pass the rating.

Here are the newly released Diamond Certified Company Report SUMMARY UPDATES.
A Reliable Handyman
A-1 Guaranteed Heating & Air, Inc.
Alameda Structural, Inc.
All Seasons Roofing & Waterproofing, Inc.
Atlas Pavers Co.
California Fencing
Cappstone, Inc.
Chasov Electrical, Voice & Data
Creative Window Fashions, Inc.
Hi Tech Termite Control of the Bay Area, Inc.
Quality First Home Improvement, Inc.
Re-Bath by Schicker
SplashWorks
Superior Plumbing & Drain Cleaning Services
The Legacy Paver Group

It’s easy to find top rated companies in the San Francisco Bay Area and Other Areas on Diamond Certified Resource.
Alameda County
Contra Costa County
El Dorado County
Fresno County
Los Angeles County
Marin County
Milwaukee County
Monterey County
Napa County
Orange County
Placer County
Sacramento County
San Benito County
San Francisco
San Joaquin County
San Mateo County
Santa Clara County
Santa Cruz County
Solano County
Sonoma County
Yolo County
Yuba County

About American Ratings Corporation
American Ratings Corporation (ARC), the creator of Diamond Certified Resource, the source for consumers who love quality local companies, rates local companies by surveying only their verified real customers to produce the country’s most accurate ratings of local companies. It also creates deeply researched company reports and consumer guides that give consumers the best companies plus the best advice for choosing a local Auto, Home, Health or Personal service type of company.

Only companies rated Highest in Quality and Helpful Expertise^® earn Diamond Certified and are backed by their Performance Guarantee. All their deeply researched reports and guides are available for free at diamondcertified.org. They also produce an annual, full-color, printed Diamond Certified Directory with 840,000 copies published in 9 geographic zones in the Greater San Francisco Bay Area. Each April, these are mailed for free to their 182,000 Diamond Certified Preferred Members and selected homeowners and companies.

Attachments

• Diamond Certified Guide to Winter-Related Services
• Diamond Certified Winter Guide Press Release

CONTACT: Greg Louie American Ratings Corporation (925) 548-3175 greglouie@diamondcertified.org 

SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) — ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that Express Scripts, the pharmacy benefits business of Evernorth Health Services, has added neffy^® (epinephrine nasal spray) to its Commercial national formularies. This decision makes neffy broadly available to millions of their commercially insured patients across the country.

neffy 2 mg is for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh ≥30 kg (66 lbs.). It is the first and only FDA-approved epinephrine nasal spray that provides a needle-free alternative to traditional injectable epinephrine and the first new delivery method for epinephrine in more than 35 years. Its simple and intuitive design enables rapid administration, helping patients and caregivers act quickly and confidently, and the small size is easy to carry. Additionally, neffy has a shelf-life of 30 months and temperatures exclusions up to 122 degrees Fahrenheit.

“The inclusion of neffy on Express Scripts’ Commercial National Formularies significantly improves access to life-saving allergy treatment,” said Sal Grausso, Head of Market Access at ARS Pharma. “This highlights the importance of providing a user-friendly solution that empowers patients and caregivers to respond quickly and effectively to severe allergic reactions, demonstrating the value of neffy in addressing unmet medical needs in the allergy community. We’re also very pleased with the quick turnaround between product introduction and the inclusion of neffy on Express Scripts’ formularies in only nine weeks. We will be working diligently to ensure continued access for as many patients and caregivers as possible.”

This expanded access aligns with ARS Pharma’s commitment to reducing barriers to care and improving outcomes for patients who rely on epinephrine during allergy emergencies. ARS Pharma anticipates other payers to join Express Scripts in providing access to neffy in the coming weeks.

To support patients in navigating coverage and affordability challenges, ARS Pharma offers a number of programs for patients and caregivers. For more information, visit www.neffy.com/savings.

About neffy^®

neffy is an intranasal epinephrine product for patients with Type I Allergic reactions including food, medications, and insect bites that could lead to life-threatening anaphylaxis.

INDICATION AND IMPORTANT SAFETY INFORMATION FOR neffy (epinephrine nasal spray)

INDICATION

neffy 2 mg is indicated for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater.

IMPORTANT SAFETY INFORMATION

It is recommended that patients are prescribed and have immediate access to two neffy nasal sprays at all times. In the absence of clinical improvement or if symptoms worsen after initial treatment, administer a second dose of neffy in the same nostril with a new nasal spray starting 5 minutes after the first dose.

neffy is for use in the nose only.

Advise patients when to seek emergency medical assistance for close monitoring of the anaphylactic episode and in the event further treatment is required.

Absorption of neffy may be affected by underlying structural or anatomical nasal conditions.

Administer with caution to patients who have heart disease; epinephrine may aggravate angina pectoris or produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported, particularly in patients with underlying cardiac disease or taking cardiac glycosides, diuretics, or anti-arrhythmics.

The presence of a sulfite in neffy should not deter use.

neffy may alter nasal mucosa for up to 2 weeks after administration and increase systemic absorption of nasal products, including neffy.

Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions.

Epinephrine can temporarily exacerbate the underlying condition or increase symptoms in patients with the following: hyperthyroidism, Parkinson’s disease, diabetes, renal impairment. Epinephrine should be administered with caution in patients with these conditions, including elderly patients and pregnant women.

Adverse reactions to neffy may include throat irritation, intranasal paresthesia, headache, nasal discomfort, feeling jittery, paresthesia, fatigue, tremor, rhinorrhea, nasal pruritus, sneezing, abdominal pain, gingival pain, hypoesthesia oral, nasal congestion, dizziness, nausea, and vomiting.

These are not all of the possible side effects of neffy. To report suspected adverse reactions, contact ARS Pharmaceuticals Operations, Inc. at 1-877-MY-NEFFY (877-696-3339) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For additional information on neffy, please see Full Prescribing Information at www.neffy.com.

About Type I Allergic Reactions Including Anaphylaxis

Type I allergic reactions are serious and potentially life-threatening events that can occur within minutes of exposure to an allergen and require immediate treatment with epinephrine, the only FDA-approved medication for these reactions. While epinephrine autoinjectors have been shown to be highly effective, there are well published limitations that result in many patients and caregivers delaying or not administering treatment in an emergency situation. These limitations include fear of the needle, lack of portability, needle-related safety concerns, lack of reliability, and complexity of the devices. There are approximately 40 million people in the United States who experience Type I Allergic reactions. Of this group, over the last three years, approximately 20 million people have been diagnosed and treated for severe Type I allergic reactions that may lead to anaphylaxis, but (in 2023, for example) only 3.2 million filled their active epinephrine autoinjector prescription, and of those, only half consistently carry their prescribed autoinjector. Even if patients or caregivers carry an autoinjector, more than half either delay or do not administer the device when needed in an emergency.

About ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy^® 2 mg (trade name EURneffy^® in the EU) (previously referred to as ARS-1), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com.

Forward-Looking Statements

Statements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to: the expected impact from the inclusion of neffy on Express Scripts’ Commercial National Formularies; ARS Pharmaceuticals’ expectation that ther payors will provide access to neffy and the timing by which they will provide such access; the needle-free profile of neffy increasing the likelihood that patients will both carry and administer adrenaline; the potential market and demand for neffy; and other statements that are not historical fact. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “anticipate,” “expects,” “if,” “may,” “potential,” “on track to,” “plans,” “will,” “would,” and similar expressions are intended to identify forward-looking statements.

These forward-looking statements are based upon ARS Pharmaceuticals’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: potential safety and other complications from neffy; the labelling for neffy in any future indication or patient population, if approved; the scope, progress and expansion of developing and commercializing neffy; the potential for payors to delay, limit or deny coverage for neffy; the size and growth of the market therefor and the rate and degree of market acceptance thereof vis-à-vis intramuscular injectable products; ARS Pharmaceuticals’ ability to protect its intellectual property position; and the impact of government laws and regulations. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption “Risk Factors” in ARS Pharmaceuticals’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the Securities and Exchange Commission on November 13, 2024. These documents can also be accessed on ARS Pharmaceuticals’ website at www.ars-pharma.com by clicking on the link “Financials & Filings” under the “Investors & Media” tab.

The forward-looking statements included in this press release are made only as of the date hereof. ARS Pharmaceuticals assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

ARS Investor Contact:
Justin Chakma
ARS Pharmaceuticals
justinc@ars-pharma.com

ARS Media Contact:
Christy Curran
Sam Brown Inc.
615.414.8668
christycurran@sambrown.com

The big story

A geographical disadvantage

A $95 billion cost

What is needed?

Need to know

What happened in the markets?

What’s happening next week?

By CNBC